Cerevance Media Center
Current News
September 19, 2023
Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease
Cerevance today announced that the first subject has been dosed in the Phase 1 clinical study evaluating the safety, tolerability, and pharmacokinetics of CVN293.
August 28, 2023
Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023
Cerevance has been named by Fierce Biotech as one of the most promising early-stage biotechnology companies in the industry in 2023, showcased on this year’s Fierce 15 list.
July 10, 2023
Cerevance to Present at the Alzheimers Association International Conference
Cerevance today announced plans to present a poster presentation at the upcoming Alzheimer’s Association International Conference (AAIC), taking place in Amsterdam, Netherlands, July 16 – 20, 2023.
June 28, 2023
Cerevance to Present at the XVI European Meeting on Glial Cells in Health and Disease
Cerevance today announced plans to present a poster presentation at the upcoming XVI European Meeting on Glial Cells in Health and Disease, taking place in Berlin, Germany, July 8 – July 11, 2023.
News Archive
October 2, 2023
Cerevance to Present at the 36th European College of Neuropsychopharmacology Congress
Cerevance to Present at the 36th European College of Neuropsychopharmacology Congress
September 5, 2023
Cerevance to Present During the 6th Annual LSX World Congress USA
Cerevance to participate in panel discussions during the 6th Annual LSX World Congress USA being held in Boston, MA, September 13-14th.
August 31, 2023
22nd Society of Chemical Industry / Royal Society of Chemistry Medicinal Chemistry Symposium
July 10, 2023
Alzheimers Association International Conference
June 28, 2023
XVI European Meeting on Glial Cells in Health and Disease
Events Archive
February 15, 2023

Characterisation of C101248: A novel selective THIK-1 channel inhibitor for the modulation of microglial NLRP3-inflammasome
Ossola, B., Rifat, A., Rowland, A., Hunter, H., Samuel Drinkall, S., Bender, C., Hamlischer, M., Teall, M., Burley, R., Barke1, D., Cadwalladr, D., Dickson, L., Lawrence, J., Harvey, J., Lizio, M., Xu, X., Kavanagh, E., Cheung, T., Sheardown, S., Lawrence, C.B., Harte, M., Brough, D., Madry, C., Matthews, K., Doyle, K., Page, K., Powell, J., Brice, N.L., Bürli, R.W., Carlton, M.B., Dawson L.A. (2023) Characterisation of C101248: a novel selective THIK-1 channel inhibitor for the modulation of m
viewNovember 21, 2022
Pharmacological Targeting of Glutamatergic Neurons within the Brainstem for Weight Reduction
Schneeberger, M., Brice, N.L., Pellegrino, K., Parolar,L., Shaked,J.T., Page,K., Marchildon, F., Barrows, D., Carroll, T.S., Tolpiko, T., Mulligan, V., Barker, D., Glen, A., Newman, R., Ortuño, M.J., Renier, N., Nectow, A.R., Cohen, P., Carlton, M., Heintz, N., Friedman, J.M. (2023) Development of an Orexin 1 Receptor Antagonist for Weight Reduction. Nat Metab. 4: 1495-1513.
viewJune 1, 2022

Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor
Mu, CW, Li, XL, Yang, Y, Zhou, Y, Wan, CH, Doyle, KJ, Ye, ND, Mistry, A, Bürli, RW (2023) Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor. Org. Proc. Res. Dev. DOI: 10.1021/acs.oprd.2c00181
viewMarch 15, 2022

The Two Pore Potassium Channel THIK-1 Regulates NLRP3 Inflammasome Activation
Drinkall, S., Lawrence, C.B., Ossola, B., Russell, S., Bender, C., Brice, N.L., Dawson, L.A., Harte, M., Brough D. (2022) The Two pore Potassium Channel THIK-1 Regulates NLRP3 Inflammasome Activation. Glia 70, 1301-1316.
viewJune 30, 2021

Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease
Brice, N.L., Schiffer, H.H., Monenschein, H., Mulligan, V.J., Page, K., Powell, J., Xu, X., Cheung, T., Burley, J.R., Sun, H., Dickson, L., Murphy, S.T., Kaushal, N., Sheardown, S., Lawrence, J., Chen, Y., Bartkowski, D., Kanta, A., Hosea, N., Dawson, L.A., Hitchcock, S.H., Carlton, M.B. (2021) Development of CVN424: a selective and novel GPR6 inverse agonist effective in models of Parkinson’s Disease. J. Pharmacol. Exp. Ther. 377: 407-416.
viewDecember 1, 2020

First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate
Sun, H., Monenschein, H., Schiffer, H.H., Reichard, H.A., Kikuchi, S., Hopkins, M., Macklin, T.K., Hitchcock, S., Adams, M., Green, J., Brown, J., Murphy, S.T., Kaushal, N., Collia, D.R., Moore, S., Ray, W.J., English, N.M., Carlton, M.B.L, Brice, N.L. (2021) First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate. J. Med Chem., 64: 9875–9890
view